(Q33392948)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21102542%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

title

New insights into postrenal transplant hemolytic uremic syndrome (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21102542%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21102542%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Moglie Le Quintrec

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21102542%20AND%20SRC:MED&resulttype=core&format=json

Véronique Frémeaux-Bacchi

16 January 2020

5

object named as

Véronique Frémeaux-Bacchi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21102542%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

author name string

Rebecca Sberro-Soussan

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21102542%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Chantal Loirat

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21102542%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

Christophe Legendre

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21102542%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

language of work or name

English

0 references

publication date

23 November 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21102542%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Nephrology

16 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21102542%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21102542%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21102542%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

page(s)

23-35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21102542%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrneph.2010.155

16 January 2020

exact match

0 references

cites work

Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

A novel non-synonymous polymorphism (p.Arg240His) in C4b-binding protein is associated with atypical hemolytic uremic syndrome and leads to impaired alternative pathway cofactor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Cyclosporine and tacrolimus-associated thrombotic microangiopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Shiga toxin-associated hemolytic uremic syndrome: absence of recurrence after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

The risk of recurrence of hemolytic uremic syndrome after renal transplantation in children

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Atypical hemolytic-uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Membrane cofactor protein and factor I: mutations and transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Familial haemolytic uraemic syndrome and an MCP mutation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Thrombomodulin mutations in atypical hemolytic-uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Insights into hemolytic uremic syndrome: segregation of three independent predisposition factors in a large, multiple affected pedigree

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

The development of atypical haemolytic-uraemic syndrome is influenced by susceptibility factors in factor H and membrane cofactor protein: evidence from two independent cohorts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Successful renal transplantation in a patient with atypical hemolytic uremic syndrome carrying mutations in both factor I and MCP.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Complement Mutation-AssociatedDe NovoThrombotic Microangiopathy Following Kidney Transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

The complement factor H R1210C mutation is associated with atypical hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

De novo gene conversion in the RCA gene cluster (1q32) causes mutations in complement factor H associated with atypical hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Atypical haemolytic uraemic syndrome associated with a hybrid complement gene

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Renal transplantation in patients with hemolytic uremic syndrome: high rate of recurrence and increased incidence of acute rejections

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Hemolytic uremic syndrome. Recurrence after renal transplantation. Groupe Coopératif de l'Ile-de-France (GCIF).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Recurrence of hemolytic uremic syndrome after renal transplantation in children: a report of the North American Pediatric Renal Transplant Cooperative Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Hemolytic uremic syndrome recurrence after renal transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Liver-kidney transplantation to cure atypical hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Functional analyses indicate a pathogenic role of factor H autoantibodies in atypical haemolytic uraemic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Successful pre-transplant management of a patient with anti-factor H autoantibodies-associated haemolytic uraemic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Anti-Factor H autoantibodies in a fifth renal transplant recipient with atypical hemolytic and uremic syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Successful renal transplantation in factor H autoantibody associated HUS with CFHR1 and 3 deficiency and CFH variant G2850T.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Recurrent atypical hemolytic uremic syndrome associated with factor I mutation in a living related renal transplant recipient

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

A missense mutation in factor I (IF) predisposes to atypical haemolytic uraemic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

A mutation in factor I that is associated with atypical hemolytic uremic syndrome does not affect the function of factor I in complement regulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Prophylactic plasma exchange in CD46-associated atypical haemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Recurrence of HUS due to CD46/MCP mutation after renal transplantation: a role for endothelial microchimerism.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Thrombomodulin is present in human plasma and urine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Local synthesis of complement component C3 regulates acute renal transplant rejection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Preventing renal ischemia-reperfusion injury using small interfering RNA by targeting complement 3 gene

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Thrombotic microangiopathy after renal transplantation in the United States

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Cyclosporine-associated thrombotic microangiopathy in renal allografts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Diagnosis of de novo localized thrombotic microangiopathy by surveillance biopsy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Post-transplant hemolytic-uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Endothelial cells in allograft rejection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Outcome of Plasma Exchange Therapy in Thrombotic Microangiopathy After Renal Transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

De novo thrombotic microangiopathy in renal allograft biopsies-role of antibody-mediated rejection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Severe vascular lesions and poor functional outcome in kidney transplant recipients with lupus anticoagulant antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Preservation of peritubular capillary endothelial integrity and increasing pericytes may be critical to recovery from postischemic acute kidney injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

De novo hemolytic uremic syndrome postrenal transplant after cytomegalovirus infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Posttransplantation cytomegalovirus-induced recurrence of atypical hemolytic uremic syndrome associated with a factor H mutation: successful treatment with intensive plasma exchanges and ganciclovir

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Postrenal transplant hemophagocytic lymphohistiocytosis and thrombotic microangiopathy associated with parvovirus b19 infection.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Calcineurin inhibitor nephrotoxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Primer: Histopathology of calcineurin-inhibitor toxicity in renal allografts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Kidney and pancreas transplantation in the United States, 1996-2005

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Cyclosporine-induced acute renal dysfunction in the rat. Evidence of arteriolar vasoconstriction with preservation of tubular function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Effects of endothelin receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Impact of immunosuppressive treatment on endothelial biomarkers after kidney transplantation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Increased risk of thrombotic microangiopathy in patients receiving a cyclosporin-sirolimus combination

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Thrombotic micro-angiopathy with sirolimus-based immunosuppression: potentiation of calcineurin-inhibitor-induced endothelial damage?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

VEGF inhibition and renal thrombotic microangiopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

mTOR inhibition induces endothelial progenitor cell death

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Endothelial Dysfunction and Cytomegalovirus Replication in Pediatric Heart Transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Endothelial damage from cytomegalovirus-specific host immune response can be prevented by targeted disruption of fractalkine-CX3CR1 interaction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Dinucleotide repeat polymorphism at the human CD59 locus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Decay-accelerating factor. Genetic polymorphism and linkage to the RCA (regulator of complement activation) gene cluster in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Influence of donor C3 allotype on late renal-transplantation outcome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

C3 polymorphisms and allograft outcome in renal transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Decay-accelerating factor modulates induction of T cell immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Primed CD8(+) T-cell responses to allogeneic endothelial cells are controlled by local complement activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Novel aspects of complement in kidney injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Calcineurin inhibitor-free immunosuppression in renal allograft recipients with thrombotic microangiopathy/hemolytic uremic syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Renal transplantation in adults with thrombotic thrombocytopenic purpura/haemolytic-uraemic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Recurrence of haemolytic-uraemic syndrome in renal transplants: a single-centre report

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Belatacept as maintenance immunosuppression for postrenal transplant de novo drug-induced thrombotic microangiopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Belatacept as immunosuppression in patient with recurrence of hemolytic uremic syndrome after renal transplantation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Plasma therapy in atypical haemolytic uremic syndrome: lessons from a family with a factor H mutation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Haemolytic uraemic syndrome caused by factor H mutation: is single kidney transplantation under intensive plasmatherapy an option?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Pulse cyclophosphamide therapy and clinical remission in atypical hemolytic uremic syndrome with anti-complement factor H autoantibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Attempted treatment of factor H deficiency by liver transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Combined kidney and liver transplantation for familial haemolytic uraemic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Hemolytic uremic syndrome: a fatal outcome after kidney and liver transplantation performed to correct factor h gene mutation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Favorable long-term outcome after liver-kidney transplant for recurrent hemolytic uremic syndrome associated with a factor H mutation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Successful split liver-kidney transplant for factor H associated hemolytic uremic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Eculizumab for paroxysmal nocturnal haemoglobinuria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Eculizumab for congenital atypical hemolytic-uremic syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Eculizumab for Atypical Hemolytic–Uremic Syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Successful treatment of transplantation-associated thrombotic microangiopathy with recombinant human soluble thrombomodulin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Therapeutic potential of complement modulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Complement. First of two parts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

Protection of endothelial cells by dextran sulfate in rats with thrombotic microangiopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2010.155

De novo thrombotic microangiopathy. An underrated complication of renal transplantation

31 March 2020

1 reference

12 December 2020

The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20.

1 reference

12 December 2020

Role of endothelin-1 and nitric oxide bioavailability in transplant-related vascular injury: comparative effects of rapamycin and cyclosporine

1 reference

12 December 2020

Thrombotic microangiopathy associated with parvovirus B 19 infection after renal transplantation

1 reference

12 December 2020

Successful liver-kidney transplantation in two children with aHUS caused by a mutation in complement factor H.

1 reference

12 December 2020